Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chlorproguanil + dapsone
- Development stage
- Phase 3
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Chlorproguanil + dapsone is a fixed-dose combination antimalarial medication. It consists of chlorproguanil, a biguanide prodrug that is metabolized into the active dihydrofolate reductase (DHFR) inhibitor chlorcycloguanil, and dapsone, a sulfone that inhibits dihydropteroate synthase (DHPS). By targeting two distinct steps in the parasite's folic acid biosynthesis pathway, the combination exhibits synergistic activity against *Plasmodium falciparum*. Developed by GSK in collaboration with the Medicines for Malaria Venture (MMV) and academic partners, it was intended as an affordable successor to sulfadoxine-pyrimethamine. However, it was withdrawn from the market and further development was halted in 2008 after clinical trials revealed a significant risk of severe hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency.
- Brand names
- Lapdap
- Other names
- CPG-DDS
02
Targets
DHPS (Dihydropteroate synthase)DHFR (Dihydrofolate reductase)
Beyond the preview
Go deeper on chlorproguanil + dapsone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chlorproguanil + dapsone.